Harvard Bioscience Inc (HBIO) stock
HBIONasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 3/3013% above fair value
$8.66−0.02 (-0.23%)
Close on Nov 20, 2026Market cap $39.42MP/E –Yield –
Harvard Bioscience free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Harvard Bioscience's free cash flow for the twelve months ending Jun 30, 2026 was -$1.12M, down 123.1% year over year. For fiscal 2025 it was $5.47M. The highest annual figure on record is $12.24M in fiscal 2023.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.47M | – |
| FY2024 | Dec 31, 2024 | -$1.20M | -109.8% |
| FY2023 | Dec 31, 2023 | $12.24M | – |
| FY2022 | Dec 31, 2022 | -$438.00K | -753.7% |
| FY2021 | Dec 31, 2021 | $67.00K | -99.2% |
| FY2020 | Dec 31, 2020 | $8.18M | +19.8% |
| FY2019 | Dec 31, 2019 | $6.83M | +259.8% |
| FY2018 | Dec 31, 2018 | $1.90M | +1036.5% |
| FY2017 | Dec 31, 2017 | $167.00K | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$363.00K | -113.6% |
| Q1 FY2026 | Mar 31, 2026 | -$1.09M | -144.0% |
| Q4 FY2025 | Dec 31, 2025 | -$545.00K | -138.3% |
| Q3 FY2025 | Sep 30, 2025 | $877.00K | – |
| Q2 FY2025 | Jun 30, 2025 | $2.67M | – |
| Q1 FY2025 | Mar 31, 2025 | $2.47M | +226.3% |
| Q4 FY2024 | Dec 31, 2024 | $1.42M | -59.0% |
| Q3 FY2024 | Sep 30, 2024 | -$1.72M | -141.6% |
| Q2 FY2024 | Jun 30, 2024 | -$1.66M | -154.8% |
| Q1 FY2024 | Mar 31, 2024 | $758.00K | -52.3% |
| Q4 FY2023 | Dec 31, 2023 | $3.47M | +42.1% |
| Q3 FY2023 | Sep 30, 2023 | $4.14M | +1901.9% |
| Q2 FY2023 | Jun 30, 2023 | $3.04M | – |
| Q1 FY2023 | Mar 31, 2023 | $1.59M | – |
| Q4 FY2022 | Dec 31, 2022 | $2.44M | – |
| Q3 FY2022 | Sep 30, 2022 | $207.00K | – |
| Q2 FY2022 | Jun 30, 2022 | -$632.00K | -212.5% |
| Q1 FY2022 | Mar 31, 2022 | -$2.46M | -377.3% |
| Q4 FY2021 | Dec 31, 2021 | -$241.00K | -109.9% |
| Q3 FY2021 | Sep 30, 2021 | -$1.14M | -210.4% |
| Q2 FY2021 | Jun 30, 2021 | $562.00K | -73.1% |
| Q1 FY2021 | Mar 31, 2021 | $886.00K | -66.3% |
| Q4 FY2020 | Dec 31, 2020 | $2.43M | +36.1% |
| Q3 FY2020 | Sep 30, 2020 | $1.03M | -63.1% |
| Q2 FY2020 | Jun 30, 2020 | $2.09M | +454.4% |
| Q1 FY2020 | Mar 31, 2020 | $2.63M | +40.9% |
| Q4 FY2019 | Dec 31, 2019 | $1.78M | -28.7% |
| Q3 FY2019 | Sep 30, 2019 | $2.80M | – |
| Q2 FY2019 | Jun 30, 2019 | $377.00K | -66.8% |
| Q1 FY2019 | Mar 31, 2019 | $1.87M | – |
| Q4 FY2018 | Dec 31, 2018 | $2.50M | – |
| Q3 FY2018 | Sep 30, 2018 | -$1.69M | -189.4% |
| Q2 FY2018 | Jun 30, 2018 | $1.14M | +381.4% |
| Q1 FY2018 | Mar 31, 2018 | -$45.00K | – |
| Q4 FY2017 | Dec 31, 2017 | -$1.15M | – |
| Q3 FY2017 | Sep 30, 2017 | $1.89M | – |
| Q2 FY2017 | Jun 30, 2017 | $236.00K | – |
| Q1 FY2017 | Mar 31, 2017 | -$808.00K | – |
See a number that looks wrong?